We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
MyoKardia Inc | NASDAQ:MYOK | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 224.91 | 224.42 | 224.91 | 0 | 01:00:00 |
Transaction Valuation*
|
Amount of Filing Fee**
|
|
$13,071,333,804.79
|
$1,426,082.52
|
|
* |
Estimated solely for purposes of calculating the filing fee pursuant to Rule 0-11(d) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Transaction Value was calculated by
adding (i) the product of (A) 53,322,904 outstanding shares (“Shares”) of common stock of MyoKardia, Inc. and (B) $225.00 (the “Offer Price”); (ii) the product of
(A) 4,745,419 Shares subject to issuance pursuant to stock options granted and outstanding and (B) $182.41, which is the difference between the $225.00 per share tender offer price and $42.59, the average weighted exercise price of such options
(all of which are “in-the-money”); (iii) the product of (A) outstanding restricted stock units in respect of 894,749 Shares subject to such restricted stock units with any applicable performance conditions deemed to be achieved at target
performance (which is the same as at maximum performance) and (B) the Offer Price; and (iv) the product of (A) 30,000 Shares which are estimated to be subject to outstanding purchase rights under the MyoKardia, Inc. Amended and Restated
Employee Stock Purchase Plan and (B) the Offer Price.
|
|
** |
The amount of the filing fee was calculated in accordance with Rule 0-11 of the Securities Exchange Act, by multiplying the Transaction Valuation by 0.0001091.
|
☑ |
Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule
and the date of its filing.
|
Amount Previously Paid: $1,426,082.52
|
|
Filing Party: Bristol-Myers Squibb Company
|
Form of Registration No.: Schedule TO
|
|
Date Filed: October 19, 2020
|
☐ |
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
|
|
☑ |
Third-party offer subject to Rule 14d-1.
|
|
☐ |
Issuer tender offer subject to Rule 13e-4.
|
|
☐ |
Going-private transaction subject to Rule 13e-3.
|
|
☐ |
Amendment to Schedule 13D under Rule 13d-2.
|
|
☐ |
Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
|
|
☐ |
Rule 14d-1(d) (Cross-Border Third Party Tender Offer)
|
Exhibit No.
|
Description
|
|
Press Release issued by Bristol-Myers Squibb Company dated November 17, 2020.
|
GOTHAM MERGER SUB INC.
|
||
By:
|
/s/ Brian P. Heaphy
|
|
Name:
|
Brian P. Heaphy
|
|
Title:
|
Vice President
|
|
BRISTOL-MYERS SQUIBB COMPANY
|
||
By:
|
/s/ Katherine R. Kelly
|
|
Name:
|
Katherine R. Kelly
|
|
Title:
|
Corporate Secretary
|
Exhibit No.
|
Description
|
|
Offer to Purchase, dated as of October 19, 2020.
|
||
Form of Letter of Transmittal (including Guidelines for Certification of Taxpayer Identification Number on IRS Form W-9).
|
||
Form of Notice of Guaranteed Delivery.
|
||
Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.
|
||
Form of Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.
|
||
Summary Advertisement, as published in The Wall Street Journal on October 19, 2020.
|
||
Joint Press Release of Bristol-Myers Squibb Company and MyoKardia, Inc. dated October 5, 2020 (incorporated by reference to Exhibit 99.1 of the Bristol-Myers Squibb Company Current Report on Form 8-K (File No. 001-01136) filed with the
Securities and Exchange Commission on October 5, 2020).
|
||
Investor Relations Presentation dated October 5, 2020 (incorporated by reference to Exhibit 99.2 of the first Bristol-Myers Squibb Company Pre-Commencement Communication on Schedule TO filed with the Securities and Exchange Commission on
October 5, 2020).
|
||
Investor Relations Call Transcript dated October 5, 2020 (incorporated by reference to Exhibit 99.3 of the first Bristol-Myers Squibb Company Pre-Commencement Communication on Schedule TO filed with the Securities and Exchange Commission on
October 5, 2020).
|
||
Transaction Infographic dated October 5, 2020 (incorporated by reference to Exhibit 99.4 of the first Bristol-Myers Squibb Company Pre-Commencement Communication on Schedule TO filed with the Securities and Exchange Commission on October 5,
2020).
|
||
Social Media Content dated October 5, 2020 (incorporated by reference to Exhibit 99.5 of the first Bristol-Myers Squibb Company Pre-Commencement Communication on Schedule TO filed with the Securities and Exchange Commission on October 5,
2020).
|
||
Enterprise Letter dated October 5, 2020 (incorporated by reference to Exhibit 99.6 of the first Bristol-Myers Squibb Company Pre-Commencement Communication on Schedule TO filed with the Securities and Exchange Commission on October 5, 2020).
|
||
Bristol-Myers Squibb Employee Q&A dated October 5, 2020 (incorporated by reference to Exhibit 99.7 of the first Bristol-Myers Squibb Company Pre-Commencement Communication on Schedule TO filed with the Securities and Exchange Commission
on October 5, 2020).
|
||
Transcript of Interview with Bristol-Myers Squibb Chief Executive Officer dated October 5, 2020 (incorporated by reference to Exhibit 99.1 of the second Bristol-Myers Squibb Company Pre-Commencement Communication on Schedule TO filed with
the Securities and Exchange Commission on October 6, 2020).
|
||
Social Media Content dated October 5, 2020 (incorporated by reference to Exhibit 99.2 of the second Bristol-Myers Squibb Company Pre-Commencement Communication on Schedule TO filed with the Securities and Exchange Commission on October 6,
2020).
|
||
MyoKardia, Inc. Current Report on Form 8-K dated October 5, 2020 (incorporated by reference to the MyoKardia, Inc. Current Report on Form 8-K (File No. 001-37609) filed with the Securities and Exchange Commission on October 5, 2020).
|
||
Email from Tassos Gianakakos, Chief Executive Officer of MyoKardia, Inc., to employees on October 5, 2020 (incorporated by reference to Exhibit 99.1 of the first MyoKardia, Inc. Solicitation/Recommendation Statement on Schedule 14D-9 filed
with the Securities and Exchange Commission on October 5, 2020).
|
Exhibit No.
|
Description
|
|
MyoKardia, Inc. Employee Q&A first used on October 5, 2020 (incorporated by reference to Exhibit 99.2 of the first MyoKardia, Inc. Solicitation/Recommendation Statement on Schedule 14D-9 filed with the Securities and Exchange Commission
on October 5, 2020).
|
||
MyoKardia, Inc. Employee Presentation provided to employees of MyoKardia, Inc. on October 28, 2020 (incorporated by reference to Exhibit (a)(1)(J) of the MyoKardia, Inc. Solicitation/Recommendation Statement on Schedule 14D-9 filed with the
Securities and Exchange Commission on October 28, 2020).
|
||
Joint Press Release of Bristol-Myers Squibb Company and MyoKardia, Inc. dated November 4, 2020.
|
||
Press Release issued by Bristol-Myers Squibb Company dated November 17, 2020.
|
||
(b)
|
Not applicable.
|
|
Agreement and Plan of Merger, dated as of October 3, 2020, by and among Bristol-Myers Squibb Company, Gotham Merger Sub Inc. and MyoKardia, Inc. (incorporated by reference to Exhibit 2.1 of the MyoKardia, Inc. Current Report on Form 8-K
(File No. 001-37609) filed with the Securities and Exchange Commission on October 5, 2020).
|
||
Confidentiality Agreement, dated as of September 17, 2020, between Bristol-Myers Squibb Company and MyoKardia, Inc.
|
||
Exclusivity Agreement, dated as of September 25, 2020, between Bristol-Myers Squibb Company and MyoKardia, Inc.
|
||
Tender and Support Agreement, dated as of October 3, 2020, between Bristol-Myers Squibb Company, Gotham Merger Sub Inc., and Tassos Gianakakos.
|
||
(g)
|
Not applicable.
|
|
(h)
|
Not applicable.
|
1 Year MyoKardia Chart |
1 Month MyoKardia Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions